257 related articles for article (PubMed ID: 1500840)
1. Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Jones TH; Figueroa CD; Smith CM; Cullen DR; Bhoola KD
J Endocrinol; 1992 Jul; 134(1):149-54. PubMed ID: 1500840
[TBL] [Abstract][Full Text] [Related]
2. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a tissue kallikrein in human prolactin-secreting adenomas.
Jones TH; Figueroa CD; Smith C; Cullen DR; Bhoola KD
J Endocrinol; 1990 Feb; 124(2):327-31. PubMed ID: 2313220
[TBL] [Abstract][Full Text] [Related]
4. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X
J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816
[TBL] [Abstract][Full Text] [Related]
5. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of specific dopamine receptors on human pituitary adenomas.
Koga M; Nakao H; Arao M; Sato B; Noma K; Morimoto Y; Kishimoto S; Mori S; Uozumi T
Acta Endocrinol (Copenh); 1987 Apr; 114(4):595-602. PubMed ID: 3577589
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
8. Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas.
Anniko M; Wersäll J
Acta Pathol Microbiol Scand A; 1981 Jan; 89(1):41-7. PubMed ID: 7223426
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine-induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas.
Anniko M; Werner S; Wersäll J
Acta Otolaryngol; 1981; 92(3-4):343-55. PubMed ID: 7324902
[No Abstract] [Full Text] [Related]
10. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.
Warfield A; Finkel DM; Schatz NJ; Savino PJ; Snyder PJ
Ann Intern Med; 1984 Dec; 101(6):783-5. PubMed ID: 6497193
[TBL] [Abstract][Full Text] [Related]
11. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
12. Effect of bromocriptine, somatostatin, and oestradiol-17 beta on hormone secretion and ultrastructure of human pituitary tumours in vitro.
Prysor-Jones RA; Kennedy SJ; O'Sullivan JP; Jenkins JS
Acta Endocrinol (Copenh); 1981 Sep; 98(1):14-23. PubMed ID: 6116372
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6, a growth promoting cytokine, is present in human pituitary adenomas: an immunocytochemical study.
Tsagarakis S; Kontogeorgos G; Giannou P; Thalassinos N; Woolley J; Besser GM; Grossman A
Clin Endocrinol (Oxf); 1992 Aug; 37(2):163-7. PubMed ID: 1327588
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemistry of prolactin-producing human pituitary adenomas.
Duello TM; Halmi NS
Am J Anat; 1980 Aug; 158(4):463-9. PubMed ID: 7006374
[TBL] [Abstract][Full Text] [Related]
15. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.
Shimon I; Hinton DR; Weiss MH; Melmed S
Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064
[TBL] [Abstract][Full Text] [Related]
16. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology.
Yamada S; Aiba T; Sano T; Kovacs K; Shishiba Y; Sawano S; Takada K
Neurosurgery; 1993 Jul; 33(1):20-7. PubMed ID: 7689191
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary.
Rotondo F; Kovacs K; Scheithauer BW; Horvath E; Bell CD; Lloyd RV; Cusimano M
Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):477-81. PubMed ID: 18633321
[TBL] [Abstract][Full Text] [Related]
19. The release of leptin and its effect on hormone release from human pituitary adenomas.
Korbonits M; Chitnis MM; Gueorguiev M; Norman D; Rosenfelder N; Suliman M; Jones TH; Noonan K; Fabbri A; Besser GM; Burrin JM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jun; 54(6):781-9. PubMed ID: 11422113
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K
Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
